Ignite Creation Date:
2024-10-26 @ 3:36 PM
Last Modification Date:
2024-10-26 @ 3:36 PM
Study NCT ID:
NCT06532565
Status:
RECRUITING
Last Update Posted:
None
First Post:
2024-07-29
Brief Title:
Study of GS-2121 Given Alone or in Combination in Adults With Advanced Solid Tumors
Sponsor:
None
Organization:
None
Study Overview
Official Title:
A Phase 1 Study to Evaluate the Safety and Tolerability of GS-2121 as Monotherapy and in Combination in Adults With Advanced Solid Tumors
Status:
RECRUITING
Status Verified Date:
2024-10
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The main goal of this first-in-human FIH study is to learn about the safety and dosing of GS-2121 when given alone or in combination with zimberelimab ZIM in participants with advanced solid tumors
The primary objectives of this study are
To assess the safety and tolerability of GS-2121 as monotherapy and GS-2121 in combination with zimberelimab in participants with advanced solid tumors
To identify the maximum tolerated dose MTD maximum administered dose MAD andor the recommended phase 2 dose RP2D of GS-2121 as monotherapy and in combination with zimberelimab in participants with advanced solid tumors
The primary objectives of this study are
To assess the safety and tolerability of GS-2121 as monotherapy and GS-2121 in combination with zimberelimab in participants with advanced solid tumors
To identify the maximum tolerated dose MTD maximum administered dose MAD andor the recommended phase 2 dose RP2D of GS-2121 as monotherapy and in combination with zimberelimab in participants with advanced solid tumors
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None